Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
Introduction: Human immunodeficiency virus (HIV) infection and the long-term use of antiretroviral therapy, especially efavirenz (EFV)-based regimens, impact lipid profiles due to insulin resistance and lead to a higher risk of metabolic diseases. Dolutegravir (DTG) is an integrase inhibitor with be...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
AboutScience Srl,
2023-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|